{"id":86602,"date":"2026-10-05T17:50:00","date_gmt":"2026-10-05T17:50:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=86602"},"modified":"2026-10-06T01:40:03","modified_gmt":"2026-10-06T01:40:03","slug":"type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/","title":{"rendered":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight"},"content":{"rendered":"<p><em>The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.<\/em><\/p>\n<p align=\"justify\">New York, USA, Oct.  05, 2026  (GLOBE NEWSWIRE) &#8212; <b>Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.<\/i><\/b><\/p>\n<p align=\"justify\">Recently published Type 2 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 2 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><b>Type 2 Diabetes Market Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">The total type 2 diabetes treatment market size is expected to grow positively by 2036 in the leading markets.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The United States accounted for the largest type 2 diabetes treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Over <b>38 million Americans<\/b>, around <b>1 in 10<\/b>, have diabetes, with<b> 90% to 95%<\/b> of cases being type 2 diabetes.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key type 2 diabetes companies, including <b>Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Ascletis Pharma, Roche, Alnylam Pharmaceuticals, Innovent Biologics, <\/b>and others, are actively working on innovative type 2 diabetes drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key type 2 diabetes therapies in clinical trials include <b>CagriSema, Survodutide (BI 456906), Retatrutide, ASC30, RG6652 (CT-996), RG6640 (CT-388), RG6849 (petrelintide), ALN-4324, IBI3032<\/b>, and others. These novel type 2 diabetes therapies are anticipated to enter the type 2 diabetes market in the forecast period and are expected to change the market.<\/li>\n<\/ul>\n<p><img loading=\"lazy\" decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" height=\"420\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/c569d4f1-beb1-47ad-8a1b-07d7f82f2c47\/type-2-diabetes-market.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" width=\"800\" data-dpi=\"96\" data-filename=\"Type-2-Diabetes-Market.jpg\" \/><\/p>\n<p align=\"justify\">Discover the future of the type 2 diabetes mellitus treatment market @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WBi6JUNOWoJC-9_Ml-phv2OruQ3FJQ8AskygHr8pylY9zOetWeG3xoV794ANFFvKv-CfUmdvhvSw08Z5O99A9RBdczG27u0RH9z0HGSw5oez37-38iTTnK9Dts2-goI9LP9aCbBe8NC1FbDRdVMUwhFlN2dCX1lc3pwL9nXuoGchfD6zdzdPniNgo5ZUEaJsFtYk9RLk_aunMK2XvzTQg3yAdJqbvn5RlcoVnHGQj645NzV7jtUvAcNJs1HHmCQX-RPobWW-xM6Rz9RAWtgMUcqufRznC6L3NvjJ1uhS2Wc=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/type-2-diabetes-market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Key Factors Driving the Growth of the Type 2 Diabetes Market\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><b>Rising Global Prevalence of Type 2 Diabetes: <\/b>The growing incidence of type 2 diabetes, driven by aging populations, sedentary lifestyles, and unhealthy dietary patterns, is expanding the patient pool and increasing demand for long-term treatment.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Growing Adoption of GLP-1\u2013Based Therapies: <\/b>GLP-1 receptor agonists and related incretin-based therapies are gaining traction due to their ability to improve glycemic control while also supporting weight management and offering potential cardiovascular benefits.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Expansion of Combination Therapies:<\/b> The use of fixed-dose combinations and multi-drug treatment strategies is increasing as patients require more intensive glycemic management over the course of disease progression.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Launch of Emerging T2DM Drugs: <\/b>The dynamics of the type 2 diabetes market are expected to change in the coming years owing to the launch of emerging therapies such as <b>agriSema <\/b>(Novo Nordisk), <b>Survodutide <\/b>(BI 456906; Boehringer Ingelheim), <b>Retatrutide <\/b>(Eli Lilly), <b>ASC30 <\/b>(Ascletis Pharma), <b>RG6652 (CT-996), RG6640 (CT-388), and RG6849 (petrelintide)<\/b> (Roche), <b>ALN-4324<\/b> (Alnylam Pharmaceuticals), <b>IBI3032 <\/b>(Innovent Biologics), and others.<\/li>\n<\/ul>\n<p align=\"justify\"><i>Aparna Thakur, Project Manager of Forecasting at DelveInsight, stated that metformin, SGLT2 inhibitors, and GLP-1 receptor-based therapies remain key pillars of T2DM management, while dual- and multi-target metabolic therapies are driving innovation. The emergence of novel combination therapies and next-generation incretin-based agents is expected to broaden treatment options and potentially reshape the T2DM market by addressing glycemic control, weight management, cardiovascular and renal outcomes, and other persistent unmet needs beyond conventional glucose lowering.<\/i><\/p>\n<p align=\"justify\"><b>Type 2 Diabetes Market Analysis<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">GLP-1 may have a broader cardiometabolic impact beyond glycemic control, as GLP-1 receptor signaling may influence blood pressure regulation and sympathetic nervous system activity.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">This underscores the potential of GLP-1\u2013based therapies to address both blood glucose management and associated cardiovascular risk factors.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Real-world data indicate a substantial challenge with GLP-1 therapy persistence, with as many as <b>64% <\/b>of patients discontinuing treatment within the first year and <b>74%<\/b> by the second year. These findings highlight the need for more convenient oral treatment options that may reduce the burden associated with injectable therapies and potentially support longer-term treatment adherence.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The marketed therapies for T2DM include <b>semaglutide (OZEMPIC, RYBELSUS), liraglutide (VICTOZA), dulaglutide (TRULICITY), tirzepatide (MOUNJARO), empagliflozin (JARDIANCE), dapagliflozin (FARXIGA), canagliflozin (INVOKANA), sitagliptin (JANUVIA), linagliptin (TRADJENTA), and saxagliptin (ONGLYZA)<\/b>.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">These established treatments offer effective glycemic control, while several also provide weight-management, cardiovascular, and renal benefits, reinforcing their role in the evolving T2DM treatment landscape.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">The T2DM GLP-1 pipeline features promising next-generation candidates, including <b>retatrutide <\/b>(Eli Lilly), <b>CagriSema <\/b>(Novo Nordisk), and <b>survodutide <\/b>(Boehringer Ingelheim), among others.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Through multi-receptor agonism and complementary metabolic mechanisms, these emerging therapies are being developed to deliver improved glycemic control, greater weight-loss efficacy, and broader cardiometabolic benefits, with the potential to address important unmet needs in T2DM management.<\/li>\n<\/ul>\n<p align=\"justify\">Learn more about the intravenous treatment for type 2 diabetes @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLV7S7bwMIEIWcaRw95gj21EzuYuZ9o_5IS2QXXK6XQziy9cTqqr4rZKGyz3OfGfKQ2UziasikBrrKSmGSe8hqZlCIN2pzvXERecrPSgM0dPsrNXZaisDQfaOYzNN0PAlerz4NGhdlL9l3kU4kTdJifGvy_DOya7xJCx160PxlSek0_EKhFJ1KPGtmx-J16DzZ9S6LgXcGsH1zygyJYx-HZvU_QJNJaQY6qIFlYkYPyq1UIS3qyN1XNVwzgDm1M\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Type 2 Diabetes Drugs<\/b><\/a><\/p>\n<p align=\"justify\"><b>Type 2 Diabetes Competitive Landscape<\/b><\/p>\n<p align=\"justify\">Some of the type 2 diabetes drugs under development include <b>CagriSema <\/b>(Novo Nordisk), <b>Survodutide <\/b>(BI 456906; Boehringer Ingelheim), <b>Retatrutide <\/b>(Eli Lilly), <b>ASC30 <\/b>(Ascletis Pharma), <b>RG6652 (CT-996), RG6640 (CT-388), and RG6849 (petrelintide)<\/b> (Roche), <b>ALN-4324<\/b> (Alnylam Pharmaceuticals), <b>IBI3032 <\/b>(Innovent Biologics), and others.<\/p>\n<p align=\"justify\"><b>Novo Nordisk\u2019s CagriSema<\/b> is a once-weekly subcutaneous fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and the GLP-1 receptor agonist semaglutide (2.4 mg). The therapy is being investigated in adults with type 2 diabetes mellitus (T2DM), with the potential to improve glycemic control while also supporting weight management and addressing cardiometabolic risk factors.<\/p>\n<p align=\"justify\"><b>Boehringer Ingelheim\u2019s Survodutide (BI 456906)<\/b> is a dual glucagon receptor (GCGR) and GLP-1 receptor agonist under evaluation for the treatment of T2DM. Through its dual-receptor mechanism, survodutide is intended to improve glucose control, promote weight loss, and deliver broader metabolic benefits. The compound is currently being evaluated in Phase III clinical development.<\/p>\n<p align=\"justify\"><b>Roche\u2019s CT-996<\/b> is a once-daily oral small-molecule GLP-1 receptor agonist under development for the treatment of obesity and type 2 diabetes. Unlike endogenous GLP-1, CT-996 is engineered as a biased agonist that preferentially activates cAMP signaling while inducing minimal to no beta-arrestin recruitment. This differentiated signaling profile is anticipated to provide robust glycemic control, substantial weight reduction, and favorable tolerability.<\/p>\n<p align=\"justify\">The anticipated launch of these emerging type 2 diabetes therapies are poised to transform the type 2 diabetes market landscape in the coming years. As these cutting-edge type 2 diabetes therapies continue to mature and gain regulatory approval, they are expected to reshape the type 2 diabetes market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n<p align=\"justify\">To know more about the advances in type 2 diabetes treatment, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLV7S7bwMIEIWcaRw95gtuqJnbrG9w_7ETi-cm875mcQABjjM0eZummZldCsCk6aLHpetLioInooH80HlDs-2lwKtqLfZnt2EwCPGIumvJBKQ9AFJAR1i4gB45pt7Go9_Ia3AaTL10KrnqgkjuN50ONiF7z-XNTQBt5OpBS394S-nMUwNhXLhM7ihUgyPxrtVnbC6iOJCqwtqcGkr_75zWVgdgJ1SbnwKA83An9sN6d8Au1W5W-pFaYe0K0-JiPoQBkHAE2TEMri94ghqpi3w==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Type 2 Diabetes Medication Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Recent Developments in the Type 2 Diabetes Market<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">In <b>September 2026, Eli Lilly and Company <\/b>announced that the U.S. Food and Drug Administration (FDA) has approved Onswik&#x2122; (insulin efsitora alfa-gobe), a once-weekly basal insulin for use alongside diet and exercise to help control blood glucose levels in adults with type 2 diabetes.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, Eli Lilly<\/b> reported positive results from three additional Phase III trials evaluating retatrutide in obesity. With these data, the clinical development package is now complete to support global regulatory submissions across obesity, obstructive sleep apnea, and knee osteoarthritis pain. The company plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, Novo Nordisk<\/b> announced the nationwide launch of Awiqli\u00ae (insulin icodec-abae) injection 700 units\/mL, the first once-weekly basal insulin approved as an adjunct to diet and exercise to improve glycemic control (blood sugar) in adults living with type 2 diabetes, following the US Food and Drug Administration (FDA) approval earlier this year.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>August 2026, Structure Therapeutics<\/b> announced that the first patients have been dosed in the Phase III ACCOMPLISH program, which includes two clinical trials evaluating aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>July 2026, Kailera Therapeutics, Inc.<\/b> announced positive topline data from two additional Phase III clinical trials of oral small molecule GLP-1 receptor agonist HRS-7535 (also known as KAI-7535) conducted by Hengrui Pharma.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>June 2026, Boehringer Ingelheim<\/b> reported detailed Phase III results from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials, demonstrating that survodutide reduced visceral fat by up to 34% and liver fat by up to 63.1% in people with obesity. The results were presented at the ADA 2026 Scientific Sessions.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In <b>June 2026, Novo Nordisk <\/b>reported positive Phase III results from the REIMAGINE 1\u20133 trials, demonstrating that CagriSema achieved significant reductions in HbA1c and body weight in adults with type 2 diabetes. The findings were presented at the ADA 2026 Scientific Sessions.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Type 2 Diabetes Epidemiology Segmentation<\/b><\/p>\n<p align=\"justify\">The type 2 diabetes epidemiology section provides insights into the historical and current type 2 diabetes patient pool and forecasted trends for the leading markets. In France, the prevalence of T2DM is <b>4.6%<\/b> in the general population, with rates increasing substantially with age. Approximately <b>one in five men <\/b>aged 70 to 85 years and one in seven women aged 75 to 85 years receive pharmacological treatment for T2DM.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=APNUQ9YreJsRvkL4Q3-0Ued5Rvrfy9KdOQL8EpeprKISJTMpuAKZ5tpikvRU-xofLD3aGKGLS6khl-0j74zRfilvbE9nWLvs82yqy2Iis1BxgozSTP48HJpX3I_kDi1frMmw8kpCRxQvpFFga_RZZDVqkUzLzUVwjRDJ21mpl5QCGcaDrO3_PLJd6gvtVQCcQkk8uGIEHsjvL6MXRAKCIYYdaNyOaTlYIVng5bEDtgQLiSUsoGnQLiQFYJIgrfgY\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>type 2 diabetes market report<\/b><\/a> proffers epidemiological analysis for the study period 2022\u20132036 in the leading markets segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Prevalent Cases of Type 2 Diabetes Mellitus<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Treated Cases of Type 2 Diabetes Mellitus<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand the type 2 diabetes drug treatment @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLV7S7bwMIEIWcaRw95gkWF9D6c_vewIbIB0A790jx3GxWNRx8h2bDzMCoDOkv-AKq_xxaHFRKZsc1bcnOP_OoJTo6UpSf-bygPYPWP2_T2_nZu_C2vJ_bzkLwStPId-R8s366PBT1JlK8fdweX87u0Dp6W_13dBnfXWxBTkUVhjVsYxCT8FwYJSIVbsmlkGOD2FjemcFdA1F-BJ6AprRkCfh6qqpjv22Ru93E65VhZYXAGp1F-wtMwFYBy-aHHl5BcKdqSCXZlKiGo_YYGsg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Type 2 Diabetes Treatment Options<\/b><\/a><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Type 2 Diabetes Market Report Metrics<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Details<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2022\u20132036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Type 2 Diabetes Market Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Type 2 Diabetes Market Epidemiology Segmentation<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Total Prevalent Cases of Type 2 Diabetes Mellitus, Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus, and Treated Cases of Type 2 Diabetes Mellitus<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Type 2 Diabetes Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Ascletis Pharma, Roche, Alnylam Pharmaceuticals, Innovent Biologics, AstraZeneca, and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Type 2 Diabetes Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">CagriSema, Survodutide (BI 456906), Retatrutide, ASC30, RG6652 (CT-996), RG6640 (CT-388), RG6849 (petrelintide), ALN-4324, IBI3032, OZEMPIC, RYBELSUS, ZEPBOUND, JARDIANCE, FARXIGA, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Scope of the <\/b><b>Type 2 Diabetes<\/b><b> Market Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Patient Population Forecast<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Therapeutics Market Size<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Pipeline Analysis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Market Size and Trends<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Market Opportunity<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Market Unmet Needs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">KOL\u2019s Views on Type 2 Diabetes<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type 2 Diabetes Market Access and Reimbursement<\/li>\n<\/ul>\n<p align=\"justify\">Discover more about next-generation type 2 diabetes drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLV7S7bwMIEIWcaRw95guT7wN6m769TXL8SDjp_DnlM_7R4yvyMZXbQmeMN7wE2ua8s-nBDmaYG2CmRETJ9IDQTY9oFuiJam5Cq9wrC4LC6IKSrKfrW1GFkNK48lFRfoGa4_w69fsBvXRHC77OgKQDRNLS9cH7mY7QU_oeM8ZwaZOW8bYrxP44FwuO0dhfFOn46JixkcKsNUAx2QGIQ-pgfG7VE9kast-tic4M9WF9x4KtSC5j2sTowdt6nSu3f\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Type 2 Diabetes Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">1<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Events<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Market Forecast Methodology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Mellitus (T2DM) Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">6.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Share (%) Distribution of T2DM By Therapies in the 7MM, in 2036<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Disease Background and Overview of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Sign and symptoms<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Risk Factors<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Subtypes of T2DM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Pathophysiology<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Biomarkers<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">7.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Diagnosis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment and Management<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treatment Algorithm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">8.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Guidelines<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Epidemiology and Patient Population of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Assumptions and Rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Mellitus Prevalent Cases in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Prevalent Cases of Type 2 Diabetes Mellitus in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Age-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Gender-specific Diagnosed Prevalent Cases of Type 2 Diabetes Mellitus in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.4.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Treated Cases of Type 2 Diabetes Mellitus in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">9.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">10<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Patient Journey of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Marketed Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Competitive landscape of marketed therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Semaglutide (OZEMPIC\/WEGOVY\/RYBELSUS): Novo Nordisk<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Drug Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Regulatory Milestones<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary of Pivotal Trials<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.5.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trial Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.2.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst&#8217;s Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">11.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bexagliflozin (BRENZAVVY): TheracosBio<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>Note: List to be continued in the report<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Emerging Type 2 Diabetes Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Competitive landscape of emerging therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">CagriSema: Novo Nordisk<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Drug Description<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Other Developmental Activities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Development<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.3.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Clinical Trials Information<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.2.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Analyst&#8217;s Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">12.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Survodutide (BI 456906): Boehringer Ingelheim<\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \"><i>Note: List to be continued in the report<\/i><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Mellitus Market: 7MM Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Findings<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Outlook of T2DM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Conjoint Analysis of T2DM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Key Type 2 Diabetes Market Forecast Assumptions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of T2DM in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.6<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of T2DM by Therapies in the 7MM<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States Type 2 Diabetes Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of T2DM in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.7.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Total Market Size of T2DM by Therapies in the United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.8<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK Type 2 Diabetes Market\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">13.9<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan Type 2 Diabetes Market<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">14<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Unmet Needs of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">15<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">SWOT Analysis of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">16<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">KOL Views of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">The United States<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.2<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">EU4 and the UK<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.3<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Japan<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.4<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Summary and comparison of Market Access and Pricing Policy Developments in 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">17.5<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Market Access and Reimbursement of Type 2 Diabetes Mellitus (T2DM) Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">18<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Bibliography<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">19<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; \">Type 2 Diabetes Market Report Methodology<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IrLV7S7bwMIEIWcaRw95guT7wN6m769TXL8SDjp_Dnm3TSfN_d53Rc_rKTA45bLv0KmUPZJ1ofN8SawnCRc6sVhnvaP0U1hMksFUvRcg0kQubBYd4645eA18vNa3M9mHAamvjFYmeT_Hq6L5LzkWU1beKesp_f4ME2tut9SFKB4y33Ol2yCxijw8RjiV6-ghQVf-UbBfGnEhZDOofHXLUG3SuxU101KWjqnK_kRfZLph9meNbNR4u2RGywmlCugx9dR7kN5YE128YIcI5HUmtASfdrZ_6euOvC8_YpRDv7o=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Type 2 Diabetes Clinical Trial Analysis\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Type 2 Diabetes Pipeline Insight <\/b><b>\u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including <b>Eli Lilly and Company, Regor Pharmaceuticals Inc., AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A\/S, Biomea Fusion Inc.,\u00a0 <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YU5f3tFIb9BYpV9wznX6DdweBvs73t5P5IZBpX-ivxJpOcTPwiLDhYCzCvhYVkjdc0VsHPZWjDlXfDd7vTPiWM7PcVDQAPmR2nFObwODw01Xa9TZrAQcuip3qD4cWY-BKXo-ciaLq7PjZe5-_0tGRciF5iIOd1jjyxexJoacsJUPPzilMilJJGzRoeXkob9uA3NAonhUrkkyk2jB0ZVumJJ9OlJgVvF1mDoCKeNqcWE=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Diabetes Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Diabetes Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including <b>vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc.,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6aWdJaczYUsNkKhjWF4wup26i4fTtWsdfmm6qaTD5ZQbYEfNa5B2uZh9sQkk68mct2RNYjocnXmsLW7Dd_h-aoSRY-LGJb3BONr1hZjZLwJYV7kIbp9qSQ4vPBnzFQatxz8KDofkVdpmNb5PUKlmlDRGHavHve4rb2uM6fQBw6gXlgCnKiW0QKRcrZSShRgS9BFoqaX-a75twZzeCo40_kzwougJyUBCVNXczlV-ev5sWtI19pnZfxKTeifj1u1-xQhFbOd62s051tfllilri8PUVnNe-RanOQEiozVijOo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>GLP-1 Agonists Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>GLP-1 Agonists Market Size, Target Population, Competitive Landscape &amp; Market Forecast <\/b><b>\u2013 2036 <\/b>report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GLP-1 agonists companies, including <b>Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk, Amgen, Viking Therapeutics, Regor Therapeutics, Carmot Therapeutics, Roche, GlaxoSmithKline, Sanofi,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hGfh-SMstcgt-rZ-1OMoBH8Eu9VrfizC9L2qzlCK7-fzI_gGIQYFgkZWVIs4svgA2RGbNrgLnJhZySpSOcwP1y1BmKaki0Zb5z37xG9Nsv1PrVKV4su7zWTDAzXugo5Q1MyOXyhvL2kYNiwhMPcfRH5kRWGE7f0er9Mb5mFPx0M4yKPiSkUITfH96XnXJCWWLlPeT83RhRxgrCEFtxR0uVzlQQvS-rrk14ss3X0r_Gco4rnI2x9oM8Xhe3Yom0VLh55EL4EmLSjYrVDOXNexdQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Obesity Market\u00a0<\/b><\/a><\/p>\n<p align=\"justify\"><b>Obesity Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key obesity companies, including <b>Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma<\/b>, and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YU5f3tFIb9BYpV9wznX6DW4ik-jjQCJ9beKhRqjRo0fQmV7aChbHcb4xo_T7sl70q0i3ZcFkLmglpPtraRa0BcuBZQatvpj-u_5ZyrfdNmnEkr8WCtOJICAohHBn6lgiqFbxXcOjfg9XwSX0taAxp3TiiPS7yUNK7tiwaRUojyst5eUdMu5-w18tzvxW-RGhJ28lx0OdihsZFq9yqEGHHZ-L9WVHihdycvZLeOFQnvdwZGqkFzr55q07rQWnh0wN\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Diabetes Drugs Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Diabetes Drugs Market Insights, Competitive Landscape, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes drugs companies, including <b>Novo Nordisk A\/S, Eli Lilly and Company, Sanofi, AstraZeneca plc, Boehringer Ingelheim, Merck &amp; Co., Inc., Johnson &amp; Johnson, Takeda Pharmaceutical Company, Novartis AG, Biocon Ltd.<\/b>, and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/ZDU0NzE1NmYtYmM5ZC00YTc3LTgyNjYtNGQ5NDY4OTQ2ZDdlLTEyMDQ5MzgtMjAyNi0xMC0wNS1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel [&#8230;]\n","protected":false},"author":1,"featured_media":86603,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-86602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-05T17:50:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-06T01:40:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight\",\"datePublished\":\"2026-10-05T17:50:00+00:00\",\"dateModified\":\"2026-10-06T01:40:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\"},\"wordCount\":2606,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\",\"name\":\"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-10-05T17:50:00+00:00\",\"dateModified\":\"2026-10-06T01:40:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight","og_description":"The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and s","og_url":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-10-05T17:50:00+00:00","article_modified_time":"2026-10-06T01:40:03+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight","datePublished":"2026-10-05T17:50:00+00:00","dateModified":"2026-10-06T01:40:03+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/"},"wordCount":2606,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/","name":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-10-05T17:50:00+00:00","dateModified":"2026-10-06T01:40:03+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/type-2-diabetes-market-to-grow-significantly-during-the-forecast-period-2026-2036-with-rising-prevalence-and-increasing-uptake-of-next-generation-therapies-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026\u20132036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/86602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=86602"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/86602\/revisions"}],"predecessor-version":[{"id":86604,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/86602\/revisions\/86604"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/86603"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=86602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=86602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=86602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}